Reigadas E, et al. - The incidence and characteristics of Clostridium difficile infection (CDI) were assessed in patients with cirrhosis, especially in those who received rifaximin. Researchers noted a high percentage of CDI cases in cirrhotic patients receiving rifaximin, mostly owing to selection of rifaximin-resistant C. difficile strains. As per multivariate analysis, rifamycin therapy and ribotype 001 were relevant risk factors for having a rifaximin-resistant C. difficile strain.